|
Post by nadathing on Aug 12, 2018 18:33:15 GMT -5
Harry: Forgot to mention that the endos at my clinic do not see pharma reps either. I'm not sure if that is standard practice with endos at other major health care facilities, but it sure as heck makes it more difficult to open their eyes to new treatment options when they wear blinders. I would imagine if patients were demanding Afrezza it may get them to look at it. That is where DTC advertising plays a huge role in creating a market.
|
|
|
Post by sweedee79 on Aug 12, 2018 18:47:55 GMT -5
I find it offensive when someone refers to Afrezza as a "niche" drug.. when that is absolutely not true.. And has nothing whatsoever to do with why the script count is low..
I don't mind differing opinions.. but at least it should be based in fact.
I understand the frustration.. but don't really appreciate someone ranting about an investment they chose to make that was clearly speculative in the first place.. And then coming here telling me to face it.. that's my choice.. I can see the numbers..i don't need this..
There are numerous reasons we find ourselves in this position.. one of the biggest ones being that Afrezza was ahead of its time.. we change the standard of care.. what I do need to face is the amount of time that it is taking and whether or not MNKD can continue the way it is in the face of people constantly attacking the company with flat out misinformation.. And lies..
Afrezza is hands down the best insulin on the market. I've seen it with my own eyes.. And our Afrezza users prove it as well.. this is what frustrates me.. why in the world would our providers not embrace this? Why continue with the same "barbaric" treatment.. And yes I agree with doc Kendall ,it is barbaric.. I think Novalog is killing my dad.. as well as a medical system that cares more about the money than it does the quality of the health care it provides..
Quality health care is only for the rich.. And our standard of care seems to not be so good anymore in this country... also too slow to change ..
|
|
|
Post by nylefty on Aug 12, 2018 18:48:39 GMT -5
Harry: Forgot to mention that the endos at my clinic do not see pharma reps either. I'm not sure if that is standard practice with endos at other major health care facilities, but it sure as heck makes it more difficult to open their eyes to new treatment options when they wear blinders. I would imagine if patients were demanding Afrezza it may get them to look at it. That is where DTC advertising plays a huge role in creating a market. I can't imagine anyone "demanding" Afrezza after seeing the current wishy-washy ad playing in (very) selected markets. Let's hope Mike and the rest of the team can find the money to produce a better ad and run it in a truly nationwide campaign.
|
|
|
Post by brotherm1 on Aug 12, 2018 20:02:21 GMT -5
What type of ad could you imagine lefty?
Also, may I ask what your user name nylefty is in reference to? Lefty O’Doul perhaps?
|
|
|
Post by peppy on Aug 12, 2018 20:11:24 GMT -5
Harry: Forgot to mention that the endos at my clinic do not see pharma reps either. I'm not sure if that is standard practice with endos at other major health care facilities, but it sure as heck makes it more difficult to open their eyes to new treatment options when they wear blinders. I would imagine if patients were demanding Afrezza it may get them to look at it. That is where DTC advertising plays a huge role in creating a market. David M. Kendall, MD, is the Chief Medical Officer for MannKind Corporation. In this role, he is responsible for leading MannKind’s scientific research, clinical development, regulatory, and medical affairs activity. Dr. Kendall’s career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and led all medical affairs activities and guided research and development strategy across multiple geographies. During this time, Dr. Kendall worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors. Prior to Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. Dr. Kendall received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College. They will see Dr. Kendall. At Park Nicollet International Diabetes Center, our mission is to ensure that every person with diabetes or at risk for diabetes receives the best possible care. hahahaha The international Diabetes center in st Louis park, MN. right. www.parknicollet.com/for-health-professionals/international-diabetes-centerseriously, our problem in Minnesota is United Health group. (I know at nauseam)
|
|
|
Post by slugworth008 on Aug 12, 2018 21:09:15 GMT -5
I find it offensive when someone refers to Afrezza as a "niche" drug.. when that is absolutely not true.. And has nothing whatsoever to do with why the script count is low.. I don't mind differing opinions.. but at least it should be based in fact. I understand the frustration.. but don't really appreciate someone ranting about an investment they chose to make that was clearly speculative in the first place.. And then coming here telling me to face it.. that's my choice.. I can see the numbers..i don't need this.. There are numerous reasons we find ourselves in this position.. one of the biggest ones being that Afrezza was ahead of its time.. we change the standard of care.. what I do need to face is the amount of time that it is taking and whether or not MNKD can continue the way it is in the face of people constantly attacking the company with flat out misinformation.. And lies.. Afrezza is hands down the best insulin on the market. I've seen it with my own eyes.. And our Afrezza users prove it as well.. this is what frustrates me.. why in the world would our providers not embrace this? Why continue with the same "barbaric" treatment.. And yes I agree with doc Kendall ,it is barbaric.. I think Novalog is killing my dad.. as well as a medical system that cares more about the money than it does the quality of the health care it provides.. Quality health care is only for the rich.. And our standard of care seems to not be so good anymore in this country... also too slow to change .. Yes indeed - Our healthcare system is bass ackwards. It's run by people who's primary interest is profit not care....and I'm old enough to remember paying 500 a month for PPO coverage for a family of 4. Those days are long gone.
|
|
|
Post by nylefty on Aug 12, 2018 21:20:34 GMT -5
What type of ad could you imagine lefty? I realize that the current ad was produced before last year's label change, but now it would be good to point out that Afrezza is a better mealtime diabetes drug than our competitors. The current ad doesn't do that and just seems to say that Afrezza is a handy adjunct in case you're presented with food unexpectedly.
|
|
|
Post by sweedee79 on Aug 12, 2018 21:25:32 GMT -5
nyleftyExactly... let's get this ball rolling ..
|
|
|
Post by mannmade on Aug 12, 2018 21:36:36 GMT -5
my ad creative (off the cuff here) would be something as follows:
Afrezza is a revolutionary new mealtime insulin that you inhale as you begin to eat not before... no more needles In addition, Afrezza has been shown to help lower Hba1c and extend time in range lowering the chances of exended hyperglycemia And when used with a cgm you can manage your diabetes in real time for the first time only with Afrezza because of its unique fast in/fast out profile all with less hypoglyceic events and less carb counting Eat what you want when you want Live life with less hassles.... Just breath For more information ask your doctor Join the revloution and live life your way...!
Of course I am sure the FDA and mnkd lawyers would have something to say about content...
|
|
|
Post by boytroy88 on Aug 12, 2018 21:44:22 GMT -5
my ad creative (off the cuff here) would be something as follows: Afrezza is a revolutionary new mealtime insulin that you inhale as you begin to eat not before... no more needles In addition, Afrezza has been shown to help lower Hba1c and extend time in range lowering the chances of exended hyeoglycemia And when used with a cgm you can manage your diabetes in real time for the first time only with Afrezza because of its unique fast in/fast out profile all with less hypoglyceic events and less carb counting Eat what you want when you want Live life with less hassles.... Just breath For more information ask your doctor Join the revloution! Of course I am sure the FDA and mnkd lawyers would have something to say about content... I like it! The "Just Breathe" campaign!
|
|
|
Post by mnkdorbust on Aug 12, 2018 23:00:25 GMT -5
my ad creative (off the cuff here) would be something as follows: Afrezza is a revolutionary new mealtime insulin that you inhale as you begin to eat not before... no more needles In addition, Afrezza has been shown to help lower Hba1c and extend time in range lowering the chances of exended hyperglycemia And when used with a cgm you can manage your diabetes in real time for the first time only with Afrezza because of its unique fast in/fast out profile all with less hypoglyceic events and less carb counting Eat what you want when you want Live life with less hassles.... Just breath For more information ask your doctor Join the revloution and live life your way...! Of course I am sure the FDA and mnkd lawyers would have something to say about content... I like it as well! The only thing I would add is something regarding Afrezza mimicking a healthy pancreas (fast in/fast out). I'm a visual person so some of Charts are worth a 1000 words to me. Like get out of the past and move into the fast lane!
|
|
|
Post by babaoriley on Aug 12, 2018 23:07:31 GMT -5
my ad creative (off the cuff here) would be something as follows: Afrezza is a revolutionary new mealtime insulin that you inhale as you begin to eat not before... no more needles In addition, Afrezza has been shown to help lower Hba1c and extend time in range lowering the chances of exended hyeoglycemia And when used with a cgm you can manage your diabetes in real time for the first time only with Afrezza because of its unique fast in/fast out profile all with less hypoglyceic events and less carb counting Eat what you want when you want Live life with less hassles.... Just breath For more information ask your doctor Join the revloution! Of course I am sure the FDA and mnkd lawyers would have something to say about content... I like it! The "Just Breathe" campaign! I like it, too! Far superior to the current situation which just sucks...
|
|
|
Post by sportsrancho on Aug 13, 2018 6:19:05 GMT -5
“Let’s do the damn thing!” 👍🏻
|
|
|
Post by peppy on Aug 13, 2018 6:49:33 GMT -5
Our afrezza commercial beats the tuejeo commercial, the guy dancing around and mowing the lawn in circles because he is on basal. Tough crowd.
|
|
|
Post by matt on Aug 13, 2018 6:52:08 GMT -5
Harry: Forgot to mention that the endos at my clinic do not see pharma reps either. I'm not sure if that is standard practice with endos at other major health care facilities, but it sure as heck makes it more difficult to open their eyes to new treatment options when they wear blinders. It is a common practice in many parts of the country to prohibit sales calls during hours when physicians are seeing patients. That is a direct result of the "share of voice" selling model employed by some pharma companies in the past where they had multiple reps from the same company detailing the same product to the same physicians. Multiply that problem by ten or fifteen drug companies calling on your clinic. At the end of the day, it is the physician's job to treat their patient and not to talk to pharma reps so I think it is a perfectly acceptable practice. It is not fair to characterize it as the physicians having blinders on. They have plenty of opportunity to learn about new products at medical meetings (which also have an exhibitors floor), print advertising in medical journals, peer-reviewed articles in major journals, continuing education dinners held after office ours, monthly hospital based "drug fairs" where all reps are welcome to sell during a period of three to four hours, and many companies sponsor lunch at the clinic in exchange for having the physicians attention while they have a sandwich. Each of these approaches have merits and flaws, but to say that a clinic "no see" policy does not allow physicians to learn about new products is not accurate. The problem for MNKD is that an increasing number of offices have a "no see" policy during clinic hours. If the receptionist will not allow the salesman to see the physician, there is very little selling that can take place.
|
|